Regulation of Monocyte-Macrophage Responses in Cirrhosis-Role of Innate Immune Programming and Checkpoint Receptors by Riva, A & Mehta, G
MINI REVIEW
published: 05 February 2019
doi: 10.3389/fimmu.2019.00167















†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 15 October 2018
Accepted: 18 January 2019
Published: 05 February 2019
Citation:
Riva A and Mehta G (2019) Regulation
of Monocyte-Macrophage Responses
in Cirrhosis—Role of Innate Immune
Programming and Checkpoint
Receptors. Front. Immunol. 10:167.
doi: 10.3389/fimmu.2019.00167
Regulation of Monocyte-Macrophage
Responses in Cirrhosis—Role of
Innate Immune Programming and
Checkpoint Receptors
Antonio Riva 1,2*† and Gautam Mehta 1,2,3*†
1 Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom, 2 Faculty of Life Sciences &
Medicine, King’s College London, London, United Kingdom, 3UCL Institute for Liver and Digestive Health, University College
London, London, United Kingdom
Many aspects of the innate immune system have been studied in cirrhosis,
and abnormalities have been described supporting both a pro-inflammatory and
anti-inflammatory phenotype of myeloid cells. However, the findings of these studies
vary by stage of disease and methodology. The recent description of the syndrome of
acute-on-chronic liver failure (ACLF) has refined our understanding of the natural history
of cirrhosis. In this context, we review the regulatory mechanisms at play that contribute
to the immune abnormalities described in advanced liver disease. Specifically, we review
the evidence for epigenetic mechanisms regulating monocyte phenotype, and the role
of checkpoint receptors on regulating innate and adaptive immune cell function.
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BACKGROUND
This is an exciting time for the field of immunotherapeutics. Advances in basic science and drug
development have progressed our understanding of regulatory mechanisms of both innate and
adaptive immune responses, which has directly led to novel immunotherapeutic agents. Moreover,
technological advances have allowed unbiased data collection from monocyte-macrophage lineage
cells, allowing a deeper understanding of their diversity and plasticity (1). The purpose of this
review is to integrate these data and place them within the context of the disease landscape of
cirrhosis.
Inflammation, and consequently innate immunity, plays a key role in the development of liver
disease at almost every stage. For example, in the early stages, monocyte-macrophage lineage cells
play a role in both the development (2, 3) and the resolution (4) of hepatic fibrosis. Understanding
and harnessing the mechanism of fibrosis resolution by hepatic macrophages is an area of active
translational research, although is beyond the scope of this review. This area has been reviewed
recently by Ramachandran et al. (5).
Acute-on-chronic liver failure (ACLF) is a recently defined syndrome, describing an acute
clinical deterioration on the background of cirrhosis, characterized by a rapid progression to multi-
organ failure and high mortality. The CANONIC study, the largest prospective study of the natural
history of cirrhosis, demonstrated that in the majority of cases (60%) a specific trigger for the acute
deterioration, such as bacterial infection or acute alcoholic hepatitis, could be identified (6). It was
also apparent from this study that dysregulated inflammation is a key feature of the syndrome.
The degree of systemic inflammation, determined by leukocyte count and C-reactive protein, was
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an independent predictor of the development and prognosis of
ACLF. However, alongside these pro-inflammatory responses,
immunodeficiency and susceptibility to infection are also features
of cirrhosis and ACLF (7, 8). The overarching term for these
immune alterations in cirrhosis is cirrhosis-associated immune
dysfunction (CAID), although the mechanisms that regulate
these diverse and dichotomous immune responses in cirrhosis
remain incompletely understood (Figure 1). Nevertheless, recent
insights into immune pathobiology in cirrhosis, along with
general advances in our understanding of regulation of
immunity, provide opportunities for novel therapies in cirrhosis.
These opportunities will be discussed in more detail in this
review.
The lines of evidence describing both features of exaggerated
systemic inflammation, as well as immunodeficiency in cirrhosis
and ACLF have been recently reviewed elsewhere (7). From
a mechanistic perspective, gut bacterial dysbiosis and the
translocation of bacterial products to mesenteric lymph nodes
and the systemic circulation have been suggested to play a
role in the development of these immunological abnormalities
in cirrhosis (7) (Figure 1). However, a clear association of
gut dysbiosis and a specific immune phenotype has not yet
been demonstrated. Moreover, most evidence from cirrhotic
patients is from single time points, and from varying severities
of liver disease, as prospectively collected data delineating the
time-course of immune phenotype in cirrhosis and ACLF is
currently lacking. As can be seen in Table 1, both pro- and anti-
inflammatory responses from monocyte-macrophage cells have
been described in cirrhosis. Further discussion of the evidence
behind these observations is provided below.
CIRCULATING MONOCYTES
Circulating monocytes play an important role in host defense,
through initiation and regulation of inflammatory responses
(18). In both humans and mice their phenotype can be
divided into two main subsets: classical (pro-inflammatory)
and non-classical (anti-inflammatory, pro-repair), which are
distinguished by surface markers (19, 20). These subsets are
primarily separated by their expression of CD14 (the co-
receptor for bacterial lipopolysaccharide, LPS) and CD16 (a
low affinity type III Fc receptor for IgG). Most circulating
monocytes, around 90%, are classical CD16− monocytes
expressing high levels of CD14 (CD16−CD14+). The remainder
CD16+ monocytes are further separated based on the expression
of CD14 among CD16+CD14+ intermediate monocytes and
CD16+CD14lo non-classical monocytes. Similar subsets are
found inmice using the Ly6C, CCR2, and CX3CR1markers, with
Abbreviations: ACLF, Acute-on-chronic liver failure; AH, Alcoholic hepatitis;
ARLD, Alcohol-related liver disease; CD, Cluster of differentiation; CTLA-4;
Cytotoxic T-lymphocyte associated protein 4; DAMP, Damage/Danger-associated
molecular pattern; DC, Decompensated cirrhosis; IFN, Interferon; IL, Interleukin;
MAIT, Mucosal-associated invariant T cells; NK, Natural killer cells; NKT, Natural
killer T cells; PAMP, Pathogen-associated molecular pattern; PD-1, Programmed
death 1; PD-L1, Programmed death ligand 1; SC, Stable cirrhosis; TIM-3, T-cell
immunoglobulin and mucin domain 3 (also known as Hepatitis A virus cellular
receptor 2, HAVCR2); TNF: Tumor necrosis factor
classical Ly6ChiCCR2+CX3CR1int monocytes and non-classical
Ly6CloCCR2−CX3CR1hi monocytes (Figure 2).
Conceptually, our understanding of the natural history of
cirrhosis has progressed over recent years with description of
the syndrome of ACLF, which describes patients with cirrhosis
who progress from stable or decompensated cirrhosis to a
rapid decline in liver function and extra-hepatic organ failure
following a superimposed “hit”. As can be seen from Table 1,
there are few studies that examine immune cell phenotype in this
stage of the disease. Monocyte dysfunction has been previously
described in ACLF in cross-sectional studies, indicating skewed
proportions between monocyte subsets with an increasing
prevalence of anti-inflammatory monocytes able to suppress pro-
inflammatory innate immune responses correlated with disease
severity. Specifically, increased numbers of monocytes expressing
the receptor tyrosine kinase Mer (MerTK) have been found in
ACLF, associated with reduced pro-inflammatory responses ex
vivo (17), and similarly, prostaglandin E2 (PGE2) levels have
been found to be elevated in ACLF and implicated in the anti-
inflammatory monocyte phenotype (16) (Figure 2). However, an
overarching mechanism for the change in monocyte phenotype
in ACLF is currently lacking.
CIRCULATING MONOCYTES RESPOND TO
SUPERIMPOSED LIVER INJURY BY
ALTERING THEIR PHENOTYPE AND
FUNCTION
The superimposed “hit” in ACLF, on the background of cirrhosis,
has been suggested to represent an acute liver insult such as
gut bacterial translocation, sepsis, alcoholic hepatitis or drug-
induced liver injury (DILI), leading to hepatocyte cell death
and the release of damage/danger-associated molecular patterns
(DAMPs) (8). Therefore, a possible hypothesis for the change in
circulating monocyte phenotype in ACLF is that it represents a
regulatory response to this superimposed liver injury (Figure 2).
The traditional dogma from mouse experiments has
been that monocytes sequentially alter their phenotype from
classical to non-classical over time, possibly in response to
micro-environmental cues. For example, following injury,
predominantly Ly6Chi monocytes are recruited from the
bone marrow and spleen to sites of injury in a CCR2- and
CCL2-dependent manner (21–23). Recent elegant experiments
using deuterium labeling in humans, and adoptive transfer
experiments in humanized mice, has demonstrated similar
transitioning in human monocytes, particularly in response to
challenge with bacterial endotoxin (24). The time course for this
transition from classical to non-classical phenotype was between
1 and 5 days, with non-classical monocytes persisting for around
12 days, thus demonstrating the importance of time course in
determining immune phenotype following infection or injury
(Figure 2).
The relevance of these observations to liver injury has also
been explored in rodent models. In a model of acetaminophen
(APAP)-induced liver injury, fate-mapping studies using
adoptive transfer of Ly6ChiCX3CR1+ monocytes demonstrated
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FIGURE 1 | Immunological phenomena associated with progression of cirrhosis. Increasing disease severity is accompanied by the establishment of a skewed
immune profile, characterized by concurrent systemic inflammation and deficient immune protection. This state of cirrhosis-associated immune dysfunction (CAID) is
crucial in increasing the risk of life-threatening microbial infection, and is in part mediated by a dysregulation of the immune checkpoint network [reviewed in (9)].
that these Ly6Chi monocytes differentiated into a Ly6Clo subset
by 72 h following liver injury, and were cleared by 96 h (25).
A further study by Dal-Secco and colleagues used CCR2-RFP
and CX3CR1-GFP double-reporter mice with a model of sterile
liver injury (26). These elegant experiments demonstrated that
CCR2hiCX3CR1lo (Ly6Chi) monocytes were initially recruited
to the site of liver injury, and over a period of 24 h transitioned
into a CCR2loCX3CR1hi (Ly6Clo) subset that was prevalent for
up to 72 h. Therefore, it is clear that liver injury can influence the
phenotype of infiltrating cells, but it remains unclear whether
this occurs in cirrhosis, and to what extent this influences the
phenotype of circulating immune cells. Nevertheless, most
studies of monocytes in ACLF have demonstrated that monocyte
dysfunction can be induced in healthy monocytes by incubation
with ACLF plasma (16, 17) (Figure 2). Therefore, liver injury
may lead to the subsequent reprogramming of circulating
cells as well as infiltrating monocytes to an anti-inflammatory
phenotype—this hypothesis merits further attention.
DE NOVO RECRUITMENT OF
ANTI-INFLAMMATORY CELLS
A further possible mechanism is the de novo recruitment of anti-
inflammatory cells. In humans, a recent study in ACLF described
an increased population of circulating CD14+CD15−HLA-DR−
myeloid-derived suppressor cells, which lead to impaired innate
and adaptive immune responses and thus contribute to the anti-
inflammatory phenotype of ACLF (27).
Another tier of complexity is the possible infiltration of
peritoneal-derived macrophages following liver injury. Recent
elegant work from Paul Kubes’ lab has demonstrated that
these peritoneal cells, described as F4/80+CD11bhiCD102+ and
GATA6+, were found to relocate to the liver within 1 h following
liver injury, to express markers associated with tissue repair, and
to be critical for survival of mice following CCl4-induced acute
liver injury (28). Furthermore, using CCR2-RFP and CX3CR1-
GFP double-reporter mice, it was clear that these peritoneal
macrophages are distinct from infiltrating peripheral blood
monocytes. Further work is required to see if these cells are




In a broader sense, the molecular mechanisms of monocyte
reprogramming are beginning to be understood and exploited.
The concept of “innate immune memory” has arisen over recent
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TABLE 1 | Monocyte-macrophages display pro- and anti-inflammatory phenotypes in end-stage liver disease.
Anti-inflammatory phenotype Pro-inflammatory phenotype
Monocyte-Macrophage: Monocyte-Macrophage:
Rimola et al. (10) In vivo: Decreased reticuloendothelial system
phagocytosis in cirrhosis (DC) compared to HC, by
tracer elimination method. This was associated with
increased incidence of bacterial infection.
Albillos et al. (11) Ex vivo: Increased activation markers (HLA-DR and
CD80) and intracytoplasmic TNFα expression in
monocytes from cirrhosis (DC) compared to HC.
Gomez et al. (12) In vivo: Decreased macrophage-mediated clearance of
IgG-coated erythrocytes in cirrhosis (mixed SC and DC).
This was associated with increased incidence of
bacterial infection.
Tazi et al. (13) Ex vivo: Greater increase in LPS-induced monocyte
TLR4 expression and TNFα release from cirrhotic
patients compared to HC.
Wasmuth et al.
(14)
Ex vivo: Decreased monocyte LPS-induced TNFα




Ex vivo: Microarray gene expression profiling of PBMCs
from ARLD cirrhosis (DC) showed decreased induction
of type-1 and type-2 IFN-stimulated genes, compared to
HC (see left column).
Gandoura et al.
(15)
Ex vivo: Microarray gene expression profiling of PBMCs
from ARLD cirrhosis (DC) compared to HC, showed
increased induction of pro-inflammatory cytokine genes
(IL-6, IL-8, TNFα), but decreased induction of type-1 and
type-2 IFN-stimulated genes, compared to HC (see right
column).
O’Brien et al. (16) Ex vivo: Plasma from DC and ACLF led to decreased
LPS-stimulated TNFα release and bacterial killing when
incubated with healthy monocyte-macrophages,
compared to plasma from stable cirrhosis.
Bernsmeier et al.
(17)
Ex vivo: Decreased monocyte LPS-induced TNFα and
IL-6 production in DC and ACLF compared to stable
cirrhosis. No change in ROS production.
years, challenging the dogma that only adaptive immune cells
have the capacity for “memory” (29). This concept describes
the phenomenon whereby an innate immune cell can mount
a qualitatively different response, either exaggerated (“trained
immunity”) or impaired (tolerance), in response to repeated
challenge. As such, it is becoming clear that innate immune
cells, particularly monocytes, can be reprogrammed at metabolic,
epigenetic, and transcriptional levels (30). In situations with
acute excessive inflammation, tolerance acts as a mechanism to
dampen the inflammatory response of the host and maintain
homeostasis to prevent tissue damage and organ failure (31, 32).
Nevertheless, in conditions such as sepsis, chronic inhibitory
effects in immune function can also lead to a state of deep and
long-lasting immunosuppression associated with a higher risk of
secondary infections and a poorer outcome (33).
Epigenetic mechanisms have been implicated in monocyte-
macrophage reprograming (30) (Figure 2). In response to
LPS or upon pathogen exposure, monocytes and macrophages
modify their histone acetylation and methylation marks,
affecting gene expression patterns upon subsequent stimulation
(34). For example, after LPS exposure, the repressive histone
modification “H3K9 dimethylation” (H3K9me2) is noted at
the promoter regions of IL-1β and TNFα (35, 36). Potential
molecular mechanisms include increased expression of histone
demethylases and deacetylases following LPS exposure (37, 38),
and several of these mechanisms have also been involved in
the reprogramming of intracellular metabolic activities affecting
the balance between glycolysis and fatty acid oxidation (39, 40)
(Figure 2). These pathways are potentially targetable: inhibitors
of the histone deacetylases sirtuin 1 and 2 (SIRT1/2) have shown
efficacy in reversing immune paralysis in mouse models of sepsis
(41, 42). Similarly, long non-coding RNAs have been shown to be
mediators of a “switch” in monocyte phenotype in sepsis and are
also potentially targetable through antisense nucleotide strategies
(43). These mechanisms deserve attention in cirrhosis and ACLF.
IMMUNE CHECKPOINTS
A further level of regulation is through interaction with adaptive
immune cells and regulation of signaling through immune
checkpoint receptors. Immune checkpoints constitute a complex
array of regulatory receptors and ligands that are expressed on
the surface of both innate and adaptive immune cells. Both co-
stimulatory and a relatively larger set of inhibitory checkpoint
pathways have been described, and it is the fine balance
between all these positive and negative signals that is responsible
for the physiological regulation of the fate and direction of
ongoing immune responses. The expression of these regulatory
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FIGURE 2 | Features of anti-inflammatory monocytes. During acute excessive inflammation monocytes can acquire an anti-inflammatory phenotype. Mechanisms
behind this phenomenon are not fully understood, but chronic and intense stimulation with PAMPs and DAMPs, consequent to microbial infection or tissue
damage/injury, seems able to facilitate it. PGE2 also seems to play a role in enabling monocyte changes. Anti-inflammatory monocytes appear tolerised to bacterial
endotoxin, possibly linked to loss of CD14. High CD16 and MerTK have also been described. Monocyte expression of inhibitory immune checkpoints has been linked
to a more suppressive phenotype, with preferential IL-10 production, and worse prognosis in cancer, infections and sepsis. Epigenetic reprogramming, and its effect
on intracellular metabolic pathways, are also observed in anti-inflammatory monocytes.
pathways is both anatomically and temporally coordinated in
order to facilitate the initiation and the termination of immune
responses. However, in situations where the inflammation or the
antigenic stimulation persist (such as sepsis, endotoxemia, or
chronic infections) inhibitory checkpoints remain upregulated
and this overwhelming negative signaling leads to immune
cell exhaustion and immunosuppression. Amongst the most
characterized inhibitory checkpoints, PD-1 and CTLA4 (with
their respective ligands PD-L1 and CD80) have demonstrated
to be novel, effective and safe immunotherapeutic targets for
cancer, and new monoclonal blocking antibodies for TIM-3 are
also currently in clinical development or tested in clinical trials
[reviewed in (9)].
Most checkpoint pathways have been first characterized as
regulators of T-cell immunity, but it is now clear that their effects
are not limited to T cells only. For instance, PD-1 is known to
also cause B andNK cell functional suppression [reviewed in (9)],
and a study in HIV patients demonstrated that monocytes can
express PD-1 upon bacterial exposure. These PD-1+ monocytes
secrete suppressive IL-10 upon PD-1 engagement (Figure 2), and
either PD-1 or IL-10 receptor blockade in these patients can
reverse adaptive HIV-specific T-cell exhaustion(44) (Figure 2).
Expression of PD-1 and PD-L1 on monocytes has also been
associated with increased mortality in septic patients (45, 46),
while expression of TIM-3 on monocytes has been linked to
a more aggressive tumor phenotype in gastric cancer patients
(47), a reduced pathogen clearance in malaria (48), preferential
production of IL-10 and suppression of IFNγ T-cell responses in
osteosarcoma patients (49). Furthermore, it has been proposed
that expression of TIM-3 on monocytes may be able to shift
the balance from IL-12 to IL-23 production and consequently
favor type-17 rather than type-1 T-cell responses, driving IL-17-
mediated inflammation at the expense of anti-pathogen IFNγ-
mediated responses (50, 51) (Figure 2). Monocyte expression of
TIM-3 is further inducible in response to TLR agonists, including
TLR4-mediated LPS stimulation, and this can have a relevant
impact in defining the immune milieu in response to bacteria or
viruses (50, 51). Importantly, blockade of monocyte TIM-3 seems
able to reverse the majority of these regulatory or suppressive
effects, supporting the restoration of effective immune responses
(48, 49, 51–53)
The above-described altered landscape of immunity in
advanced liver disease is influenced by checkpoint receptor
expression. A paper published in 2015 by one of the authors
(AR) was the first to demonstrate that PD-1 and TIM-3 are
key in defining this altered immune landscape, and monocyte
hyper-stimulation with gut-derived bacterial LPS was found to
be the driving factor for these immune dysfunctions (54). We
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observed that adaptive antibacterial T-cell responses in patients
with advanced alcohol-related liver disease were prominently
skewed toward the production of suppressive IL-10 in response
to LPS stimulation, and this was directly correlated with loss
of IFNγ production and hyper-expression of PD-1 and TIM-
3 on several immune cell subsets, including T, NK, and NKT
cells (54), but not—interestingly—innate-like antibacterial T cells
(mucosal-associated invariant T cells, orMAIT) (55). Stimulation
with LPS dose-dependently induced PD-1, TIM-3 and IL-10
expression, but blockade of TLR4 and CD14 on monocytes
completely abolished these effects; furthermore, blocking PD-
1 and TIM-3 suppressed IL-10 and restored the production of
antibacterial IFNγ, indicating that the immune defects observed
in patients with alcohol-related liver disease may be reversible
(54). Similar findings have been described in patients with non-
alcoholic sepsis and also in mouse models of sepsis-induced
endotoxin-driven liver inflammation [reviewed in (9)].
These results indicate that immune checkpoint blockade may
be an effective treatment strategy for the restoration of defective
antibacterial immunity in patients with end-stage liver disease.
Furthermore, the lack of inflammation observed in our study
and the good safety profiles of anti-checkpoint monoclonal
antibodies currently used in cancer and sepsis suggest that
immune checkpoint blockade may be a safe treatment approach
also in end-stage liver disease, where conventional treatment
options are currently very limited.
CONCLUSION
In conclusion, the innate and adaptive immune systems have
many tiers of regulation which have been shown to be
dysfunctional in cirrhosis. However, prospectively collected data
delineating the time course of immune phenotype by stage of
disease in cirrhosis remains scarce. Innate cell reprogramming,
through metabolic or epigenetic mechanisms or by targeting
checkpoint receptors, remains an attractive area for translational
development, although parallel development of reliable immune
biomarkers in cirrhosis will be required for immunotherapies to
reach their full potential.
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